|1.||Kumar, S: 2 articles (10/2009 - 01/2007)|
|2.||Jerome, C P: 1 article (10/2009)|
|3.||Stroup, G B: 1 article (10/2009)|
|4.||Oh, H: 1 article (01/2007)|
|5.||Veber, D F: 1 article (01/2007)|
|6.||Dare, L: 1 article (01/2007)|
|7.||Vasko-Moser, J A: 1 article (01/2007)|
|8.||Hwang, S-M: 1 article (01/2007)|
|9.||Rickard, D J: 1 article (01/2007)|
|10.||Blake, S M: 1 article (01/2007)|
01/01/2007 - "Administration of SB-462795 to medically ovariectomized or normal monkeys resulted in an acute reduction in both serum and urinary markers of bone resorption within 1.5 h after dosing, and this effect lasted up to 48 h depending on the dose administered. "
10/01/2009 - "By histomorphometry, relacatib reduced indices of bone resorption and formation at cancellous sites as did alendronate. "
01/01/2007 - "Our data indicate that SB-462795 potently inhibits human cathepsin K in osteoclasts, resulting in a rapid inhibition of bone resorption both in vitro and in vivo in the monkey. "
01/01/2007 - "SB-462795 inhibited endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of approximately 45 nM and approximately 70 nM, respectively. "
01/01/2007 - "A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys."
|3.||Alendronate (Alendronate Sodium)
|4.||Biological Markers (Surrogate Marker)